ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Eight brokerages rate ANI Pharmaceuticals a “Moderate Buy,” split between four buy and four hold ratings. The average 12-month price target is $105.83, above the reported share price of $76.87.
• Quarterly results exceeded expectations: ANI reported adjusted earnings of $2.21 per share versus the $2.04 consensus estimate, while revenue rose 25.8% year over year to $266.04 million.
• Institutional ownership is strong, but insiders have been selling: Institutions own 76.05% of the stock, with several major investment firms establishing or increasing positions. Insiders sold 18,987 shares worth approximately $1.55 million over the past 90 days.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been given an average rating of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $105.8333.

ANIP has been the subject of several recent analyst reports. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings cut ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Canaccord Genuity Group lowered their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 18,987 shares of company stock valued at $1,546,405 in the last 90 days. 8.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals during the third quarter worth approximately $32,992,000. Ranger Investment Management L.P. purchased a new stake in ANI Pharmaceuticals in the second quarter worth $28,406,000. Deutsche Bank AG bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $26,775,000. Balyasny Asset Management L.P. raised its stake in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $21,372,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Trading Up 1.1%

NASDAQ ANIP opened at $76.87 on Wednesday. The stock's 50 day moving average is $80.65 and its 200 day moving average is $78.97. The firm has a market capitalization of $1.77 billion, a PE ratio of 16.57 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a twelve month low of $70.15 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the previous year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals will post 8.03 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source